Advanced Drug Delivery across the Blood–Brain Barrier
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 2906
Special Issue Editors
Interests: drug delivery; peptide therapeutics; nucleic acid therapeutics; cancer therapy; immunotherapy; nanotechnology; formulation
Interests: drug delivery; functional peptide; therapeutics; siRNA therapeutics; CNS therapy; cancer therapy; autoimmune disease therapy; nanotechnology
Special Issue Information
Dear Colleagues,
Delivering therapeutic agents across the blood–brain barrier (BBB) remains a significant challenge in the treatment of neurological diseases. The BBB, composed of tightly packed endothelial cells, restricts the passage of most therapeutic agents into the central nervous system. Thus, overcoming this barrier is essential for the effective treatment of neurological disorders.
This Special Issue aims to highlight recent advancements in drug delivery strategies that cross the BBB. By elucidating the mechanisms behind successful delivery strategies and reporting on innovative approaches, we seek to advance our understanding and capabilities in this crucial area of drug delivery.
Contributions featuring innovative technologies, targeted delivery systems, new applications in various diseases, and insights into BBB physiology are strongly encouraged. Through collaborative efforts and interdisciplinary dialogue, this Special Issue seeks to stimulate advancements in drug delivery across the BBB and pave the way for enhanced treatments for neurological diseases.
Prof. Dr. Kun Cheng
Dr. Zhen Zhao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood–brain barrier (BBB)
- central nervous system (CNS)
- drug delivery
- neurological disease
- nanotechnology
- transport mechanism
- targeted delivery
- BBB permeability
- glioblastoma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
